HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

On the efficacy of parenteral chondroitin sulfate in patients with osteoarthRitis in the presence of grade 1 functional joint failure

DOI: https://doi.org/10.29296/25877305-2022-01-05
Issue: 
1
Year: 
2022

I. Sarvilina, MD OOO «Novomeditsina» (New Medicine) Medical Center, Rostov-on-Don

It is necessary to reconsider the use of drugs affecting the pathobiochemical pathways in the development of cartilaginous tissue structural changes in functional joint failure (FJF) in the presence of osteoarthritis (OA). Objective. To evaluate the efficacy of the parenteral formulation of the pharmaceutically active substance chondroitin sulfate (CS; Chondroguard®, CS-Bioactive© Bioiberica S.A.U., Spain, manufactured by the ZAO «FarmFirma “Sotex», Russia) in patients with Stage II knee OA (KOA) and grade 1 FJF. Subjects and methods. A 50-day open-label, prospective, controlled, randomized trial was conducted according to inclusion/exclusion criteria. The trial enrolled 82 patients with Stage II KOA, grade 1 FJF, who were divided into two groups: 1) 42 patients received CS (Chondroguard®, 100 mg/ml) intramuscularly every other day; the first three 1-ml injections; and if well tolerated, the fourth and next 2-ml injections (a 50-day treatment cycle included 25 injections); 2) 40 patients took celecoxib at a dose of 200 mg/day, which can be reduced to 100 mg/day and discontinued. On days 0 and 50, the investigators assessed pain intensity using a visual analogue scale (VAS), Lequesne’s functional indices, WOMAC, and joint ultrasound data and the safety of therapy using the WHO and Naranjo scales. The data were statistically processed applying the Statistica 10.0 software (StatSoft, Inc., USA). Results. Chondroguard® therapy was well tolerated by patients and was accompanied by a significant improvement in pain intensity scores according to VAS (U test=7.79; p

Keywords: 
therapy
osteoarthritis
joint functional failure
chondroitin sulfate
Chondroguard



References: 
  1. Nasonova V.A., Folomeeva O.M. Mediko-sotsial'noe znachenie XIII klassa boleznej dlja naselenija Rossii. Nauchno-prakticheskaja revmatologija. 2001; 1: 7–11 [Nasonova V.A., Folomeeva O.M. Medical-social importance of the xiii class of diseases JCD X for russian population. Rheumatology Science and Practice. 2001; 1: 7–11 (in Russ.)].
  2. Lawrence R.C., Felson D.T., Helmick C.G. et al. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008; 58 (1): 26–35. DOI: 10.1002/art.23176
  3. Murphy L., Schwartz T.A., Helmick C.G. et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008; 59 (9): 1207–13. DOI: 10.1002/art.24021
  4. Rossijskie klinicheskie rekomendatsii. Revmatologija. Pod red. E.L. Nasonova. M.: GEOTAR-Media, 2020; 448 s. [Rossiiskie klinicheskie rekomendatsii. Revmatologiya. Pod red. E.L. Nasonova. M.: GEOTAR-Media, 2020; 448 s. (in Russ.)].
  5. Balabanova R.M., Erdes Sh.F. Dinamika rasprostranennosti revmaticheskih zabolevanij, vhodjaschih v HIII klass MKB-10, v populjatsii vzroslogo naselenija Rossii za 2000–2010 gg. Nauchno-prakticheskaja revmatologija. 2012; 50 (3): 10–2 [Balabanova R.M., Erdes S.F. Trends in the prevalence of rheumatic diseases in ICD-10 in the adult population of the Russian Federation over 2000–2010. Rheumatology Science and Practice. 2012; 50 (3): 10–2 (in Russ.)]. DOI: 10.14412/1995-4484-2012-702
  6. Litwic A., Edwards M.H., Dennison E.M. et al. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013; 105 (1): 185–99. DOI: 10.1093/bmb/lds038
  7. Leyland K.M., Gates L.S., Sanchez Santos M.T. et al. The PCCOA Steering Committee. Knee osteoarthritis and time to all cause mortality in six community based cohorts: an international meta analysis of individual participant level data. Aging Clin Exp Res. 2021; 33: 529–45. DOI: 10.1007/s40520-020-01762-2
  8. Pal C.P., Singh P., Chaturvedi S. et al. Epidemiology of knee osteoarthritis in India and related factors. Indian J Orthop. 2016; 50 (5): 518–22. DOI: 10.4103/0019-5413.189608
  9. Erdes Sh.F., Folomeeva O.M. Invalidnost' vzroslogo naselenija Rossii, obuslovlennaja revmaticheskimi zabolevanijami. RMZh. 2007; 15 (26): 1946–50 [Erdes Sh.F., Folomeeva O.M. Invalidnost’ vzroslogo naseleniya Rossii, obuslovlennaya revmaticheskimi zabolevaniyami. RMZh. 2007; 15 (26): 1946–50 (in Russ.)].
  10. Cross M., Smith E., Hoy D. et al. The global burden of hip and knee osteoarthritis: Estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014; 73 (7): 1323–30. DOI: 10.1136/annrheumdis-2013-204763
  11. Samuels J., Krasnokutsky S., Abramson S.B. Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis. 2008; 66: 244–50.
  12. Samuel A., Kanimozhi D. Outcome measures used in patient with knee osteoarthritis: With special importance on functional outcome measures. Int J Health Sci. 2019; 13 (1): 52–60.
  13. Klinicheskaja farmakologija. Natsional'noe rukovodstvo. Pod red. Belousova Ju.B., Lepahina V.K., Kukesa V.G., Petrova V.I. M.: GEOTAR-Media, 2009 [Klinicheskaya farmakologiya. Natsional’noe rukovodstvo. Pod red. Belousova Yu.B., Lepakhina V.K., Kukesa V.G., Petrova V.I. M.: GEOTAR-Media, 2009 (in Russ.)].
  14. Alekseeva L.I. Preparaty zamedlennogo dejstvija v lechenii OA. RMZh. 2012; 7: 389–93 [Alekseeva L.I. Preparaty zamedlennogo deistviya v lechenii OA. RMZh. 2012; 7: 389–93 (in Russ.)].
  15. Reginster J.-Y., Veronese N. Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. Aging Clin Exp Res. 2021; 33 (1): 37–47. DOI: 10.1007/s40520-020-01643-8
  16. Voloshin V.P., Eremin A.V., Sankaranarajanan S.A. i dr. Issledovanie effektivnosti dejstvija preparata Hondrogard (hondroitina sul'fat) u patsientov s osteoartrozom. Trudnyj patsient. 2015; 13 (3): 2932 [Voloshin V.P., Eryomin A.V., Sankaranarayanan S.A. et al. Study on Effectiveness of Hondrogard (Chondroitin Sulfate) in Patients with Osteoarthritis. Trudnyi patsient. 2015; 13 (3): 2932 (in Russ.)].
  17. Lila A.M., Gromova O.A., Torshin I.Ju. i dr. Molekuljarnye effekty Hondrogarda pri osteoartrite i gryzhah mezhpozvonochnogo diska. Nevrologija, nejropsihiatrija, psihosomatika. 2017; 9 (3): 88–97 [Lila A.M., Gromova O.A., Torshin I.Yu. et al. Molecular effects of chondroguard in osteoarthritis and herniated discs. Neurology, Neuropsychiatry, Psychosomatics. 2017; 9 (3): 88–97 (in Russ.)]. DOI: 10.14412/2074-2711-2017-3-88-97
  18. Gonartroz. Klinicheskie rekomendatsii [Gonartroz. Klinicheskie rekomendatsii (in Russ.)]. URL: https://cr.minzdrav.gov.ru/recomend/667_1
  19. Koksartroz. Klinicheskie rekomendatsii [Koksartroz. Klinicheskie rekomendatsii (in Russ.)]. URL: https://cr.minzdrav.gov.ru/recomend/666_1
  20. Singh J.A., Noorbaloochi S., MacDonald R. et al. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015; 1: CD005614. DOI: 10.1002/14651 858.cd005 614.pub2
  21. Torshin I.Ju., Lila A.M., Naumov A.V. i dr. Metaanaliz klinicheskih issledovanij effektivnosti lechenija osteoartrita preparatom Hondrogard. FARMAKOEKONOMIKA. Sovremennaja Farmakoekonomika i Farmakoepidemiologija. 2020; 13 (4): 399–410 [Torshin I.Yu., Lila A.M., Naumov A.V. et al. Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (4): 388–99 (in Russ.)]. DOI: 10.17749/2070-4909/farmakoekonomika.2020.066
  22. Lila A.M., Tkacheva O.N., Naumov A.V. i dr. Mesto i rol' parenteral'noj formy hondroitina sul'fata v terapii osteoartrita: mul'tidistsiplinarnyj Konsensus. RMZh. 2021; 6: 68–74 [Lila A.M., Tkacheva O.N., Naumov A.V. et al. Place and role of the parenteral form of chondroitin sulfate in the treatment of osteoarthritis: multidisciplinary Consensus. RMJ. 2021; 6: 68–74 (in Russ.)].
  23. Kellgren J.H., Lawrence J.S. Radiographic assessment of osteoarthritis. Ann Rheum Dis. 1957; 16 (4): 494–502. DOI: 10.1136/ard.16.4.494
  24. Smirnov A.V. Atlas rentgenologicheskoj diagnostiki pervichnogo osteoartroza. M.: IMA-PRESS, 2010 [Smirnov A.V. Atlas of x-ray diagnosis of primary osteoarthritis. M.: IMA-PRESS, 2010 [(in Russ.)].
  25. Zhang W., Doherty M., Peat G. et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010; 69 (3): 483–9. DOI: 10.1136/ard.2009.113100